FTSE 100 investing: 2 bargain buys I’d consider today

While the FTSE 100 index remains elevated, these two shares look like long-term bargain buys to Manika Premsingh.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A slew of FTSE 100 companies have released their results today, but investors are not impressed with all of them. Curiously enough, this is despite their posting decent results or their long-term prospects.

I think this makes it a good time to consider buying these shares at a bargain. Here are two of them. 

#1. Hikma Pharmaceuticals: defensives drop

The FTSE 100 drug manufacturer Hikma Pharmaceuticals (LSE:HIK) turned in a broadly robust set of numbers for 2020 today. 

Its revenue is up 6% and operating profit has risen by 17%. It has also increased its dividend amount by 15%. Its earnings per share are down, but I would be more worried if this was reflected in the dividends, which it is not. Hikma is also optimistic in its outlook for 2021.

Yet, its share price is down almost 6% as I write. I reckon this is for two reasons.

One, defensives are out of favour. AstraZeneca, for example, is down 25% from the highs seen in July last year. Hikma too, has witnessed a broad share price softening since the market rally started. 

Two, in my observation it sometimes takes a day or two before the results’ impact shows up on the share price. I think that might be the case with Hikma, though other explanations are possible too. For instance, its operating profit is below analysts’ forecasts. We will know more soon. 

In the meantime, I think it is a good stock to buy. Actually, going by its financials, any time is a good time to buy it, but more so now when its share price is down.

There is, of course, the risk that defensives will remain out of favour as stock markets stay elevated. That would mean that its share price could continue to remain weak. 

But I see little chance of that happening. 

Hikma shares have a price-to-earnings (P/E) ratio of around 10 times right now. As other stocks start looking expensive, I reckon investors will circle back around to the likes of bargain buys like HIK.

#2. Mondi: FTSE 100 long-term play

The FTSE 100 packaging and paper provider Mondi (LSE: MNDI) released its results too, resulting in a small share price drop. Both its revenues and profits have been impacted in 2020, but I think of Mondi as a long-term play.

Its fortunes are tied to the online sales market, which is really the way we will shop in the future. Digital sales have boomed in 2020, acclerating the process. This has positively impacted companies from e-grocers like Ocado to warehousers like Segro. MNDI is no different, which could otherwise have suffered far more in a lockdown. 

I think over time it will benefit even more. Investors clearly think so too, going by the fact that its share price recently touched multi-year highs. Moreover, its P/E is still at 11 times right now, indicating that it is a bargain buy compared to many other peers. I think it will start rising again. 

The risk I see here is that MNDI is that it may take a while to get its financial act back together. Till then its share price could really languish. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh owns shares of AstraZeneca and Ocado Group. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »